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Abstract
Background: Inheritance of a germline mutation in one of the DNA mismatch repair (MMR) genes MLH1, MSH2, MSH6, and 
PMS2 causes a high risk of colorectal and other cancers (Lynch Syndrome). Use of aspirin has been shown to be associated 
with a reduced risk of colorectal cancer for the general population as well as for MMR gene mutation carriers. The aim 
of this study was to determine whether use of aspirin and ibuprofen in a nontrial setting is associated with the risk of 
colorectal cancer risk for MMR gene mutation carriers.
Methods: We included 1858 participants in the Colon Cancer Family Registry who had been found to have a pathogenic 
germline mutation in a MMR gene (carriers). We used weighted Cox proportional hazards regression to estimate hazard 
ratios (HRs) and 95% confidence intervals (CIs). All statistical tests were two-sided.
Results: A total of 714 carriers (38%) were diagnosed with colorectal cancer at a mean age of 42.4 (standard deviation 10.6) 
years. A reduced risk of colorectal cancer was associated with aspirin use (for 1 month to 4.9 years: HR = 0.49, 95% CI = 0.27 to 
0.90, P = .02; for ≥5 years: HR = 0.25, 95% CI = 0.10 to 0.62, P = .003) and ibuprofen use (for 1 month to 4.9 years: HR = 0.38, 95% 
CI = 0.18 to 0.79, P = .009; for ≥5 years: HR = 0.26, 95% CI = 0.10 to 0.69, P = .007), compared with less than one month of use.
Conclusion: Our results provide additional evidence that, for MMR gene mutation carriers, use of aspirin and ibuprofen 
might be effective in reducing their high risk of colorectal cancer.






Lynch Syndrome, previously termed Hereditary Non-Polyposis 
Colorectal Cancer, is an inherited susceptibility to colorectal and 
other cancers. Lynch Syndrome is caused by germline mutations 
in the DNA mismatch repair (MMR) genes MLH1, MSH2, MSH6, 
and PMS2, which encode proteins that identify and excise DNA 
mismatches (1). The prevalence of MMR gene mutation carri-
ers in the general population has been estimated to range from 
approximately one in 370 to one in 3100, depending on the 
population and calculation assumptions (2,3). Lynch Syndrome 
causes 2% to 4% of all colorectal cancers and 10% to 15% of colo-
rectal cancers diagnosed before the age of 50 years (4,5).
The average cumulative risk of colorectal cancer for MMR 
gene mutation carriers is substantial: about 50% by age 70 years 
for MLH1 and MSH2 carriers (6). However, there is evidence 
that there is very wide variation in risk even across carriers of 
mutations in the same gene (6), such that the majority of car-
riers are either at only modestly increased risk or at very high 
risk, rather than being clustered around the average risk. These 
observations raise the possibility that risk for mutation carriers 
is strongly determined by other genetic and/or environmental 
factors and that risk might be reduced substantially if relevant 
modifiable factors can be identified.
The main risk-reduction strategy for mutation carriers is 
regular screening with colonoscopy and polypectomy, which 
has been shown to reduce both colorectal cancer incidence and 
mortality (7). Accordingly, screening guidelines recommend that 
MMR mutation carriers have colonoscopy every one to two years 
from age 25 years, or five years earlier than the youngest colorec-
tal cancer diagnosis in the family, whichever comes first (8–12).
Another potential colorectal cancer risk reduction approach, 
for which evidence has been accumulating over the last two 
decades, is chemoprevention using aspirin or other nonsteroi-
dal anti-inflammatory drugs (NSAIDs). Several randomized con-
trolled trials (RCT) and large cohort studies have consistently 
shown that use of aspirin and other NSAIDs reduces the risk of 
colorectal cancer for the general population (13–16). Five RCTs 
have also shown a protective effect of aspirin against colorectal 
adenoma for individuals with a personal history of colorectal 
neoplasia (17,18).
For MMR gene mutation carriers, evidence of a protective 
effect of aspirin use was provided by the CAPP2 RCT, the first 
trial of aspirin chemoprevention with cancer as the primary 
endpoint. At the end of two years of treatment, there was no 
evidence for an effect of daily high-dose (600 mg) aspirin on 
colorectal cancer risk (19). However, an analysis after a mean 
follow-up of 56 months found that the mutation carriers who 
had been randomly assigned to aspirin had about a 40% reduc-
tion in colorectal cancer incidence compared with the control 
patients (20). The effect of low-dose aspirin and other NSAIDs 
including ibuprofen on colorectal cancer risk for carriers outside 
a trial setting is unknown.
We report here results from the largest observational study 
to date investigating the association between use of aspirin and 
the risk of colorectal cancer for MMR gene mutation carriers and 
present the first analysis of a potential association with use of 
ibuprofen, a widely available nonaspirin NSAID.
Methods
Study Sample
The study sample consisted of participants in the Colon Cancer 
Family Registry who had been genetically tested and found to 
be carriers of a germline pathogenic mutation in an MMR gene. 
A detailed description of the Colon Cancer Family Registry design 
and recruitment strategy has been presented elsewhere (21) and 
is available at http://coloncfr.org. Briefly, between 1997 and 2012, 
families were recruited through: 1) population-based probands 
with newly diagnosed colorectal cancer identified by state or 
regional population cancer registries in the United States (WA, 
CA, AZ, MN, CO, NH, NC, and HI), Australia (Victoria), and Canada 
(Ontario); and 2)  clinic-based probands from multiple-case 
families referred to family cancer clinics in the United States 
(Mayo Clinic, Rochester, MN, and Cleveland Clinic, Cleveland, 
OH), Canada (Ontario), Australia (Melbourne, Adelaide, Perth, 
Brisbane, Sydney), and New Zealand (Auckland). We obtained 
permission from probands to contact their relatives to seek 
their enrollment in the Colon Cancer Family Registry. Informed 
consent was obtained from all study participants, and the study 
protocol was approved by the research ethics review boards of 
each recruitment center.
Data Collection
Epidemiologic and demographic information was collected using 
in-person interviews, telephone interviews, or mailed question-
naires at the time of recruitment. The questionnaires asked about 
participants’ characteristics; personal and family history of can-
cer; history of cancer screening; history of polyps, polypectomy 
and other surgeries; and use of aspirin, ibuprofen, and other 
medications. The detailed questionnaires used by each Colon 
Cancer Family Registry center are available at: http://coloncfr.
org/questionnaires. Reported cancer diagnoses and ages at diag-
nosis were confirmed if possible using pathology reports, medi-
cal records, cancer registry reports, and death certificates. We 
attempted to obtain blood samples from all study participants 
and tumor tissue from colorectal cancer–affected participants.
MMR Gene Mutation Testing
Screening for germline mutations in MLH1, MSH2, MSH6, and 
PMS2 was performed for all population-based probands who had 
a colorectal tumor that showed evidence of impaired MMR func-
tion by either tumor microsatellite instability (MSI) or a lack of 
MMR protein expression by immunohistochemistry, or both. For 
clinic-based families, screening was performed for the youngest 
colorectal cancer case patient regardless of MSI or MMR protein 
expression status. For the MLH1, MSH2, and MSH6 genes, muta-
tion testing was performed by Sanger sequencing or denaturing 
high performance liquid chromatography (dHPLC), followed by 
confirmatory DNA sequencing. Large duplication and deletion 
mutations were detected by Multiplex Ligation Dependent Probe 
Amplification (MLPA) according to the manufacturer’s instruc-
tions (MRC Holland, Amsterdam, the Netherlands) (21–23). 
For the PMS2 gene, mutation testing involved a modified pro-
tocol from Senter et  al. (24), in which exons 1–5, 9, and 11–15 
were amplified using three long-range polymerase chain reac-
tions (PCRs) followed by nested exon-specific PCR/sequencing, 
while the remaining exons (6, 7, 8, and 10) were amplified and 
sequenced directly from genomic DNA. Large-scale deletions in 
PMS2 were detected using the P008-A1 MLPA kit (MRC Holland, 
Amsterdam, the Netherlands). Relatives of probands with a 
pathogenic MMR germline mutation (25) who had provided a 
blood sample were tested for the specific mutation identified in 
the proband. In this study, we included all probands and their 
relatives who had been found to be carriers of a germline patho-
genic mutation in a MMR gene.







Aspirin intake and ibuprofen intake were the two main expo-
sure variables. Never use was defined as answering “no” to 
“Have you ever taken (aspirin/ibuprofen) at least twice a week 
for a month or longer?” Ever use was defined as answering “yes” 
to “Have you ever taken (aspirin/ibuprofen) at least twice a week 
for a month or longer?”
Duration of aspirin/ibuprofen use was based on the question 
“How long, in total, have you taken this medication for at least 
twice a week for a month or longer?” We calculated the age at 
first use of aspirin/ibuprofen (under the assumption that dura-
tion was continuous and recent) by subtracting the reported 
duration of use from the age at interview. Then, we calculated 
the duration of use as the total number of years of (aspirin/ibu-
profen) use between the age at first use and the age at colorectal 
cancer diagnosis or censoring.
Those who answered “yes” to the question “Have you ever 
taken (aspirin/ibuprofen) at least twice a week for a month or 
longer?” and reported a duration that was shorter than the time 
interval between age at colorectal cancer diagnosis or censoring 
and age at interview, were classified as never users.
Statistical Analysis
We conducted weighted Cox proportional hazards regression 
analyses, with age as the time scale, to estimate the associa-
tions of use of aspirin only, ibuprofen only, and aspirin and/or 
ibuprofen with the risk of colorectal cancer. Time at risk started 
from birth and ended at age at first diagnosis of colorectal can-
cer (n = 714), age of diagnosis of non-colorectal cancer (n = 304), 
polypectomy (n = 306), or age at interview (n = 534), whichever 
occurred first. We chose to censor at age at any cancer diagno-
sis because cancer treatment could alter subsequent colorectal 
cancer risk. Similarly, we censored at age at first polypectomy 
because removal of polyps markedly reduces colorectal cancer 
risk (7). This prevents the potential confounding of colonoscopy 
screening on the associations between the exposure variables 
and colorectal cancer risk.
Colorectal cancer cases with a strong family history and/
or early onset were preferentially tested for MMR gene muta-
tions in the Colon Cancer Family Registry. Therefore, selec-
tion of the mutation carriers to be included in this study was 
not random with respect to disease status—i.e., there was an 
excess of colorectal cancer case patients compared with what 
would be expected in an unselected cohort of carriers. To adjust 
for this nonrandom sampling, we created a “synthetic” cohort 
using the weighted cohort approach described by Antoniou et al. 
(26), which has been previously applied in studies of disease-
risk modifiers for carriers of rare genetic mutations (27–29). This 
method involves giving affected and unaffected carriers age-
specific relative weights based on their sampling probabilities 
so that the age-specific incidence in the synthetic cohort is con-
sistent with the incidence estimated for carriers in the general 
population (26).
In this study, as described in detail by Pande et  al. (30), 
population-based estimates of colorectal cancer incidence for 
five-year intervals (31) were multiplied by the relative risks of 
colorectal cancer for MMR gene mutation carriers (32) to obtain 
age-specific incidences (see Supplementary Table  1, available 
online). These age-specific incidences were used to calculate 
sampling fractions in order to weight mutation carriers so that 
for each five-year interval the proportion of affected carriers in 
the synthetic cohort equaled the proportion of affected carriers 
in the general population. A simulation study of this approach 
using Cox regression showed that allowing for nonrandom sam-
pling by using external age-specific incidences led to unbiased 
estimates of risk modifiers when the external incidences were 
correctly specified (26).
Aspirin-only, ibuprofen-only, and aspirin and/or ibuprofen 
use were fit separately as binary (ever vs never), and categorical 
(<1 month, 1 month, to 4.9 years, and ≥5 years) variables, and 
corresponding hazard ratios (HRs) and 95% confidence intervals 
(CIs) were estimated for associations with colorectal cancer risk. 
The proportional hazards (PH) assumption was tested by exam-
ining the relationship between the scaled Schoenfeld residuals 
and survival time (33).
Model-building strategies were based on the “purposeful 
selection” method described by Hoshmer and Lemeshow (34). 
Selection of covariates for inclusion in the multivariable models 
was based on statistical significance at the 25% level in the uni-
variate models and on clinical importance for any variables not 
selected with this criterion. The following factors were consid-
ered as potential confounders: 1) year of birth (1914–43, 1944–54, 
1955–65, 1966–90); 2)  sex; 3)  country of recruitment; 4)  ethnic-
ity; 5)  education; 6)  smoking status (never, former, current); 
7)  number of alcohol drinks per day; 8)  body mass index two 
years before interview (underweight [<18.5 kg/m2], normal [18.5–
24.9 kg/m2], overweight [25.0–29.9 kg/m2], obese [≥30 kg/m2]); 
9) history of diabetes (yes, no); 10) multivitamin supplement use 
(<1 month vs ≥1 month); 11)  regular physical activity (at least 
30 minutes per week for at least three months); 12)  acetami-
nophen (<1 month vs ≥1 month); and 13) laxatives(<1 month vs 
≥1 month) for both sexes and 14) hormone replacement therapy 
use (<6 vs ≥6 months); and 15) number of live births (none, 1, 
2, ≥3) for women. Variables that did not meet the PH assump-
tion were included as time-dependent covariates in the model. 
Missing values of covariates were coded as an additional cat-
egory to allow inclusion of as many carriers as possible in the 
multivariable model fits. Tests for interactions between expo-
sures and potential effect modifiers were performed using the 
log-likelihood ratio test.
To identify any potential survival bias on recruitment, we 
further conducted an analysis restricted to carriers who were 
diagnosed with colorectal cancer, or censored, within five years 
prior to the interview. To determine whether censoring at pol-
ypectomy influenced the estimated associations, we conducted 
an analysis using colorectal neoplasia (i.e., either colorectal 
cancer or colorectal polyps) as the outcome. We also conducted 
an analysis restricted to carriers for whom there was complete 
covariate data (i.e., carriers with a missing value for any covari-
ate were excluded).
We applied the Huber-White robust variance estimation by 
clustering on family membership to allow for a correlation in 
risk between family members (35,36). All statistical tests were 
two-sided, and, following convention, nominal statistical signifi-
cance was determined at P values of less than .05. Analyses were 
performed using Stata 13 (37).
Results
From the Colon Cancer Family Registry, we identified a total 
of 2003 carriers of a pathogenic mutation in a MMR gene. Of 
these, we excluded 11 (0.5%) because they were censored before 
age 18 years and 134 (6.7%) because they had missing data on 
both main exposure variables. Excluded carriers did not differ 
in main characteristics from those who were entered into the 
analyses (details not shown).
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The study therefore involved 1858 MMR gene mutation car-
riers from 748 families (25% population-based), of whom 1038 
(55.8%) were female, who contributed a total of 77 494 person-
years. Of these, 681 carried a mutation in MLH1, 873 in MSH2, 
204 in MSH6, and 100 in PMS2, and 714 (38%) were diagnosed 
with colorectal cancer at a mean age at diagnosis of 42.4 years 
(SD = 10.6). A total of 653 (91%) reported cancers were confirmed 
by pathology, clinical, or cancer-registry records. The time inter-
val between age at colorectal cancer diagnosis or censoring and 
age at interview was on average 9.2 (SD = 9.9) years for carriers 
with colorectal cancer and 9.9 (SD 9.4) years for carriers without 
colorectal cancer (P = .14).
Characteristics of participating MMR gene mutation carri-
ers are presented in Table 1. Of all carriers, 117 (6.7%) reported 
having used aspirin only for at least one month, 126 (7.2%) 
reported having used ibuprofen only for at least one month, 
and 286 (14.3%) reported having used aspirin and/or ibuprofen 
for at least one month. The prevalence of aspirin and ibupro-
fen use by country, age group, and sex is shown in Table 2. The 
prevalence of aspirin use for carriers affected with colorectal 
cancer and unaffected carriers was 6.5% and 6.9%, respectively 
(Supplementary Table 2, available online).
Table  3 presents the results of the univariate and multi-
variable Cox regression models and the confounders included 
in each model. A reduced risk of colorectal cancer was associ-
ated with ever use of: aspirin only (HR = 0.43, 95% CI = 0.25 to 
0.75, P = .003), ibuprofen only (HR = 0.35, 95% CI = 0.19 to 0.63, 
P = .001), and aspirin and/or ibuprofen (HR = 0.41, 95% CI = 0.28 
to 0.61, P < .001). A longer duration of use was associated with 
a lower risk of colorectal cancer; aspirin-only use (for 1 month 
to 4.9 years: HR = 0.49, 95% CI = 0.27 to 0.90, P = .02; for ≥5 years: 
HR = 0.25, 95% CI = 0.10 to 0.62, P = .003) and ibuprofen-only use 
(for 1 month to 4.9 years: HR = 0.38, 95% CI = 0.18 to 0.79, P = .009; 
for ≥5 years: HR = 0.26, 95% CI = 0.10 to 0.69, P = .007) (Table 3). 
These inverse associations are illustrated in Figures 1 and 2 for 
aspirin and ibuprofen, respectively.
Table  4 presents the results of the multivariable analyses 
separately for men and women. The inverse associations with 
aspirin only, ibuprofen only, and aspirin and/or ibuprofen were 
similar to those from the combined analysis, and there was no 
evidence that they differed by sex (P > .7 for all interactions). 
Table 5 presents the results of the multivariable analyses sepa-
rately for mutation carriers by the specific MMR gene mutated. 
There was no evidence that the strengths of association differed 
by gene (P > .2 for all interactions).
In the analysis restricted to carriers diagnosed with colo-
rectal cancer or censored within five years prior to their inter-
view (n  =  1213, 65%), the results were similar to those from 
the main analysis (Supplementary Table  3, available online). 
Similar results were also observed when we used colorectal 
neoplasia (either polyp or colorectal cancer) as the outcome 
(Supplementary Table 4, available online). Finally, in the analysis 
restricted to carriers with complete covariate data, the results 
were similar to the main analysis (data not shown). All models 
were tested and there was no evidence that the PH assumption 
was violated.
Discussion
This study includes the largest sample of confirmed MMR 
gene mutation carriers assembled to date to investigate the 
association between aspirin use and colorectal cancer risk in 
the context of Lynch Syndrome. We estimated that, for carri-
ers of pathogenic germline mutations in MMR genes, aspirin 
use for at least one month was associated with a decrease of 
approximately 60% in the risk of colorectal cancer. A  recent 
meta-analysis of 10 cohort studies investigating the asso-
ciation between duration of aspirin use and the risk of colo-
rectal cancer for the general population estimated 10% (95% 
CI = 8% to 12%) and 18% (95% CI = 14% to 22%) reductions in 
colorectal cancer risk for five and 10 years’ use, respectively 























































* Age at first diagnosis of colorectal cancer for affected carriers; age at first polypectomy or diagnosis of non-colorectal cancer or interview for unaffected carriers 
(whichever came first). BMI = body mass index; CRC = colorectal cancer; MMR = mismatch repair.
† Underweight (<18.5 kg/m2), normal (18.5–24.9 kg/m2), overweight (25.0–29.9 kg/m2), obese (≥30 kg/m2).
‡ Former smokers defined as carriers who had smoked at least one cigarette per day for at least three months and had quit more than two years before age at 
colorectal cancer or censored age; current smokers defined as carriers who had smoked at least one cigarette per day for at least three months and continued within 
two years of age at colorectal cancer or censored age.
§ Regular physical activity defined as any physical activity for at least 30 minutes per week for at least three months.
‖ At least twice a week.
¶ Only for female carriers.
Table 1. Continued






gene mutation carriers was substantially stronger than that 
observed for the general population, particularly for aspirin 
use for more than five years (P =  .002 for difference between 
estimates based on the test of interaction proposed by Altman 
Table 2. Prevalence of aspirin and ibuprofen intake in mismatch repair gene mutation carriers by country, sex, and age category*
NSAID use Country/age group, y Men No. (%) Women No. (%) Overall No. (%)
Aspirin only USA
≤35 4 (9.3) 1 (3.0) 5 (6.5)
36–45 5 (10.8) 4 (7.1) 9 (8.8)
46–55 7 (9.2) 5 (6.4) 12 (7.8)
>55 20 (20.6) 12 (11.5) 32 (15.9)
All 36 (13.7) 22 (8.1) 58 (10.9)
Australia/New Zealand
≤35 3 (2.6) 6 (4.1) 9 (3.4)
36–45 5 (6.0) 5 (5.2) 10 (5.5)
46–55 4 (3.6) 3 (2.4) 7 (3.0)
>55 7 (6.4) 16 (8.8) 23 (7.9)
All 19 (4.5) 30 (5.5) 49 (5.1)
Canada
≤35 1 (5.2) 1 (3.7) 2 (4.3)
36–45 2 (10.0) 0 (0) 2 (4.8)
46–55 0 (0) 1 (2.5) 1 (1.5)
>55 2 (5.0) 3 (4.8) 5 (4.9)
All 5 (4.8) 5 (3.3) 10 (3.9)
Overall 60 (7.6) 57 (5.9) 117 (6.7)
Ibuprofen only USA
≤35 4 (9.0) 6 (15.3) 10 (12.0)
36–45 2 (4.7) 5 (8.3) 7 (6.8)
46–55 7 (9.5) 7 (8.6) 14 (9.0)
>55 3 (3.9) 3 (3.2) 6 (3.5)
All 16 (6.8) 21 (7.7) 37 (7.3)
Australia/New Zealand
≤35 6 (5.1) 11 (7.4) 17 (6.4)
36–45 7 (8.3) 13 (12.5) 20 (10.7)
46–55 8 (7.1) 14 (10.6) 22 (9.0)
>55 9 (8.0) 11 (6.3) 20 (6.9)
All 30 (7.0) 49 (8.8) 79 (8.0)
Canada
≤35 0 (0) 1 (3.7) 1 (2.2)
36–45 1 (5.0) 2 (8.0) 3 (6.6)
46–55 2 (7.4) 2 (4.1) 4 (5.3)
>55 0 (0) 2 (3.1) 2 (2.0)
All 3 (3.0) 7 (4.2) 10 (3.8)
Overall 49 (6.4) 77 (7.7) 126 (7.2)
Aspirin and/or ibuprofen USA
≤35 10 (19.2) 10 (22.7) 20 (20.8)
36–45 10 (19.2) 12 (17.9) 22 (18.4)
46–55 16 (18.3) 16 (15.9) 32 (16.9)
>55 27 (25.2) 22 (17.4) 49 (21.0)
All 63 (21.1) 60 (17.7) 123 (19.3)
Australia/New Zealand
≤35 10 (8.2) 19 (12.0) 29 (10.3)
36–45 12 (13.3) 18 (16.3) 30 (15.0)
46–55 13 (10.8) 18 (12.9) 31 (11.9)
>55 18 (14.5) 31 (15.3) 49 (15.0)
All 53 (11.6) 86 (14.1) 139 (13.0)
Canada
≤35 1 (5.2) 2 (6.9) 3 (6.2)
36–45 3 (13.6) 2 (7.6) 5 (10.4)
46–55 2 (6.6) 4 (7.8) 6 (7.4)
>55 2 (4.7) 8 (11.1) 10 (8.7)
All 8 (7.0) 16 (8.9) 24 (8.2)
Overall 124 (14.3) 162 (14.3) 286 (14.3)
* NSAID = nonsteroidal anti-inflammatory drugs.






and Bland [39]). Our findings are more consistent with the risk 
reduction found by Burn et  al. in the CAPP2 trial, in which 
MMR gene mutation carriers had a 58% (95% CI = 14% to 81%) 
reduction in colorectal cancer risk from use of 600 mg of aspi-
rin daily for an average period of two years (this result was 
detected after a mean follow-up period of 4.6 years) (20). Our 
finding that the associations were similar when colorectal 
neoplasia was the outcome is consistent with use of NSAIDs 
delaying initiation of adenomas. This finding contrasts with 
the CAPP2 study, which did not find evidence for a short-term 
(two-year) reduction in the risk of adenoma (19). However, it is 
consistent with several RCTs of people with familial adenoma-
tous polyposis (FAP), which found evidence that use of NSAIDs 
reduces the size and the number of colorectal polyps (40–44). 
It should be noted, however, that FAP and Lynch Syndrome are 
very different clinically and genetically.
Our analysis is the first reported investigation of a potential 
association between ibuprofen and the risk of colorectal can-
cer in the context of Lynch Syndrome. Use of ibuprofen only for 
at least one month was associated with a 65% decrease in the 
risk of colorectal cancer. This finding is consistent with pre-
vious evidence of an inverse association between nonaspirin 
NSAIDs, particularly those of the propionic acid derivatives 
class such as ibuprofen, and the risk of colorectal cancer for 
the general population. A case-control study by Reeves and col-
leagues has shown that ibuprofen might have a greater benefi-
cial effect against colorectal cancer than aspirin (57% vs 21% 
risk reduction) (45).
Table 3. Univariate and multivariable hazard ratios for associations between aspirin and ibuprofen use and the risk of colorectal cancer for 
mismatch repair gene mutation carriers
NSAID use






Never user† 622 1572 25 743 1 (Ref) 1 (Ref)
Aspirin-only user 48 117 2505 0.48 (0.33 to 0.71) <.001 0.43 (0.25 to 0.75) .003
 1 month to 4.9 years 38 96 1904 0.49 (0.31 to 0.76) .002 0.49 (0.27 to 0.90) .02
 ≥5 years 10 21 601 0.45 (0.21 to 0.92) .03 0.25 (0.10 to 0.62) .003
Ibuprofen-only user 30 126 1373 0.33 (0.20 to 0.55) <.001 0.35 (0.19 to 0.63) .001
 1 month to 4.9 years 22 92 1010 0.36 (0.20 to 0.66) .001 0.38 (0.18 to 0.79) .009
 ≥5 years 8 34 363 0.25 (0.11 to 0.58) .001 0.26 (0.10 to 0.69) .007
Aspirin and/or ibuprofen user 92 286 4548 0.40 (0.30 to 0.54) <.001 0.41 (0.28 to 0.61) <.001
 1 month to 4.9 years 66 210 3196 0.42 (0.29 to 0.59) <.001 0.44 (0.27 to 0.69) <.001
 ≥5 years 26 76 1352 0.36 (0.22 to 0.57) <.001 0.34 (0.19 to 0.62) <.001
* Adjusted for year of birth (1914–43, 1944–54, 1955–65, 1966–90) and average lifetime alcohol intake (0, 1, ≥2 drinks per day) and stratified by sex, country (USA, 
Australia/ New Zealand, Canada), cigarette smoking status (never, former, current), regular physical activity (at least 30 minutes per week for at least three months), 
and multivitamin intake (<1 month, ≥1 month). All statistical tests were two-sided. CI = confidence interval; HR = hazard ratio; n = number of colorectal cancer cases; 
N = total number of carriers; NSAID = nonsteroidal anti-inflammatory drugs.
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Figure 1. Cox regression analysis for association between aspirin only use and the risk of colorectal cancer over time for mismatch repair gene mutation carriers. Adjusted 
for year of birth (1914–43, 1944–54, 1955–65, 1966–90) and average lifetime alcohol intake (0, 1, ≥2 drinks per day) and stratified by sex, country (USA, Australia/ New Zea-
land, Canada), cigarette smoking status (never, former, current), regular physical activity (at least 30 minutes per week for at least three months), and multivitamin intake 
(<1 month, ≥1 month). Upper and lower dashed lines represent upper and lower limit of 95% confidence interval, respectively. Solid line represents the hazard ratio.






The potential chemopreventive effect of NSAIDs on colorec-
tal cancer has been recognized since the late 1980s (46) and is 
strongly supported by experimental data (47). The mechanism 
of action that defines NSAIDs as a class is their ability to inhibit 
the cyclooxygenase (COX) activity of the enzyme prostaglan-
din G/H-synthase, which is expressed as two distinct isoforms, 
designated COX-1 and COX-2 (48). However, the exact mecha-
nism by which aspirin reduces colorectal cancer risk is yet to 
be understood. Most colorectal cancers progress through the 
action of multiple molecular mechanisms that involve cycloox-
ygenases, Wnt–β-catenin, MAP kinase, cytokines, and growth 
factors (14). The effect of NSAIDs on colorectal neoplasia could 
be mediated by their ability to restore apoptosis through the 
inhibition of the COX pathway (49,50). In addition to the COX-
inhibition pathway, several other possible mechanisms have 
been described (51,52).
Recently, Greenspan and colleagues investigated the 
effect of ibuprofen on biochemical pathways in both human 
Table 4. Sex-specific multivariable hazard ratios for associations between aspirin and ibuprofen use and the risk of colorectal cancer for mis-





(95% CI) P n N Person-years
HR†
(95% CI) P
Never user‡ 338 696 14 137 1 (Ref) 284 876 11 606 1 (Ref)
Aspirin-only user 29 60 1501 0.43 (0.21 to 0.86) .02 19 57 1004 0.42 (0.17 to 1.03) .06
 1 month to 4.9 years 23 50 1128 0.45 (0.21 to 0.97) .04 15 46 776 0.54 (0.21 to 1.41) .21
 ≥5 years 6 10 373 0.32 (0.10 to 0.96) .04 4 11 228 0.15 (0.01 to 1.32) .09
Ibuprofen-only user 15 49 693 30 (0.14 to 0.67) .004 15 77 680 0.35 (0.14 to 0.86) .02
 1 month to 4.9 years 11 36 517 0.38 (0.14 to 1.01) .05 11 56 493 0.36 (0.12 to 1.09) .07
 ≥5 years 4 13 176 0.21 (0.05 to 0.86) .03 4 21 187 0.33 (0.09 to 1.15) .08
Aspirin and/or ibuprofen user 52 124 2580 0.41 (0.24 to 0.68) .001 40 162 1968 0.42 (0.23 to 0.78) .006
 1 month to 4.9 years 38 94 1808 0.42 (0.24 to 0.74) .003 28 116 1388 0.39 (0.18 to 0.84) .02
 ≥5 years 14 30 772 0.20 (0.06 to 0.62) .005 12 46 580 0.52 (0.21 to 1.28) .16
* Adjusted for year of birth (1914–43, 1944–54, 1955–65, 1966–90) and average lifetime alcohol intake (0, 1, ≥2 drinks per day) and stratified by country (USA, Australia/ 
New Zealand, Canada), cigarette smoking status (never, former, current), regular physical activity (at least 30 minutes per week for at least three months), and multi-
vitamin intake (<1 month, ≥1 month). All statistical tests were two-sided. CI = confidence interval; HR = hazard ratio; n = number of colorectal cancer cases; N = total 
number of carriers; NSAID = nonsteroidal anti-inflammatory drugs.
† Adjusted for year of birth (1914–43, 1944–54, 1955–65, 1966–90) and number of live births (none, 1, 2, 3, or more) and stratified by country (USA, Australia/ New 
Zealand, Canada), cigarette smoking status (never, former, current), regular physical activity (at least 30 minutes per week for at least three months), hormone 
replacement therapy use (<6 months, ≥6 months), and multivitamin intake (<1 month, ≥1 month).
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Figure 2. Cox regression analysis for association between ibuprofen only use and the risk of colorectal cancer over time for mismatch repair gene mutation carriers. 
Adjusted for year of birth (1914–43, 1944–54, 1955–65, 1966–90) and average lifetime alcohol intake (0, 1, ≥2 drinks per day) and stratified by sex, country (USA, Australia/ 
New Zealand, Canada), cigarette smoking status (never, former, current), regular physical activity (at least 30 minutes per week for at least three months), and multi-
vitamin intake (<1 month, ≥1 month). Upper and lower dashed lines represent upper and lower limit of 95% confidence interval, respectively. Solid line represents the 
hazard ratio.






adenomas and colorectal cancers in vitro and showed that ibu-
profen is effective in inhibiting Wnt–β-catenin nuclear translo-
cation in both human adenomas and in colorectal cancer cells. 
This study confirmed that a NSAID can suppress β-catenin, a 
key mediator of colon tumorigenesis, in sporadic adenomas fol-
lowing long-term treatment in patients (53). Overall, it should 
be noted that it is currently unknown whether the biological 
processes that have been discovered so far and that potentially 
underlie the association between NSAIDs and sporadic colorec-
tal cancers also apply to Lynch Syndrome–associated colorectal 
cancers.
One of the strengths of our study is that we were able to 
adjust for recognized potential confounding variables, includ-
ing alcohol consumption, cigarette smoking, hormone replace-
ment therapy, and multivitamin use. The Colon Cancer Family 
Registry had established standardized and uniform protocols for 
collection of epidemiologic data, family history, and cancer his-
tory. It had also undertaken comprehensive mutation screening 
(21). To minimize bias because of patients having been selected 
on the basis of phenotype, we used a weighted cohort approach 
(26).
A limitation of our study is the inability to assess the gra-
dient in risk with specific doses of aspirin and ibuprofen, as 
this information was not collected by the questionnaires. 
Long-term follow-up of a current trial could help resolve this 
issue and determine optimal aspirin treatment regimen. No 
studies investigating the dose-response effect of ibuprofen 
on colorectal cancer risk have been published. There have 
been concerns about the potential side effects of long-term 
aspirin use, particularly regarding the risk of hemorrhagic 
strokes and gastrointestinal bleeding beyond age 70  years 
(54,55). NSAIDs (perhaps particularly nonaspirin NSAIDs) are 
also associated with side effects, including what is called 
diaphragm disease—a non-neoplastic overgrowth in the 
small intestine (56,57). More research is needed for a better 
understanding of the determinants of these side effects (58). 
Recently, a comprehensive review and synthesis of the avail-
able evidence on the benefits and harms has found a strong 
net benefit for the prophylactic use of aspirin to reduce the 
incidence of colorectal and other cancers, and mortality, in 
the general population (59). However, recent results from the 
Women’s Health Study have shown that the potential benefit 
of aspirin use in relation to cancer outcomes might only apply 
after age 64  years (60). In the context of Lynch Syndrome, 
where absolute cancer risk is high, use of aspirin as a chemo-
prevention strategy for colorectal cancer is likely to present 
a more favorable and consistent benefit-harm profile than in 
the general population.
Another limitation of this study is the possibility that the 
findings may have been affected by recall or response bias, 
given that data on the intake of aspirin and ibuprofen use and 
other variables were collected at the time of recruitment, and 
therefore, for those affected, after their diagnosis of colorectal 
cancer. Differential recall on exposures between participants 
diagnosed with colorectal cancer (as well as other cancers 
or polypectomy) and those who were censored at the time 
of interview is also a potential source of bias in our study. 
Similarly, our definition of duration of aspirin/ibuprofen use 
was based on the assumption that the use was continuous 
and recent. However, participants might have used aspirin/
ibuprofen intermittently and we were unable to account for 
this variation in our analysis. Further, study participants 
might have used NSAIDs other than aspirin and ibuprofen 
that were not included in the Colon Cancer Family Registry 
questionnaire. It is therefore possible that some participants 
were misclassified as nonusers in the analysis. Finally, as the 
carriers with poorer survival were less likely to be included in 
this study (as they were less likely to be alive to be recruited 
Table 5. Multivariable hazard ratios for associations between aspirin and ibuprofen use and the risk of colorectal cancer by mismatch repair 
gene mutated
MMR gene/NSAID use n N Person-years HR* (95% CI) P
MLH1
 Never user† 276 600 11 043 1 (Ref)
 Aspirin-only user 13 30 609 0.34 (0.13 to 0.86) .02
 Ibuprofen-only user 13 40 603 0.91 (0.32 to 2.55) .86
 Aspirin and/or ibuprofen user 32 81 1499 0.43 (0.21 to 0.87) .02
MSH2
 Never user† 266 751 10 975 1 (Ref)
 Aspirin-only user 18 51 887 0.52 (0.19 to 1.45) .22
 Ibuprofen-only user 8 53 344 0.27 (0.08 to 0.85) .03
 Aspirin and/or ibuprofen user 32 122 1505 0.39 (0.20 to 0.74) .004
MSH6
 Never user† 50 148 2330 1 (Ref)
 Aspirin-only user 6 21 352 0.23 (0.04 to 1.06) .06
 Ibuprofen-only user 5 24 242 0.16 (0.03 to 0.72) .02
 Aspirin and/or ibuprofen user 12 56 643 0.27 (0.04 to 1.75) .17
PMS2
 Never user† 30 73 1395 1 (Ref)
 Aspirin-only user 11 15 657 1.78 (0.56 to 5.67) .33
 Ibuprofen-only user 4 9 184 1.60 (0.33 to 7.59) .55
 Aspirin and/or ibuprofen user 16 27 901 0.70 (0.33 to 1.47) .35
* Adjusted for sex, country (USA, Australia/ New Zealand, Canada), average lifetime alcohol intake (0, 1, ≥2 drinks per day), year of birth (1914–43, 1944–54, 1955–65, 
1966–90), cigarette smoking status (never, former, current), regular physical activity (at least 30 minutes per week for at least three months), and multivitamin 
intake (<1 month, ≥1 month), where possible. All statistical tests were two-sided. CI = confidence interval; HR = hazard ratio; n = number of colorectal cancer cases; 
MMR = DNA mismatch repair; N = total number of carriers; NSAID = nonsteroidal anti-inflammatory drugs.
† Never users defined as carriers who reported not having taken either aspirin or ibuprofen or both for at least one month.






and give a blood sample), there is the possibility of survival 
and selection bias if age at onset and survival of case patients 
were related to exposure variables and/or mutation status. 
However, our sensitivity analysis restricted to carriers who 
were diagnosed with colorectal cancer or censored within five 
years prior to the interview showed findings similar to the 
main analysis.
In summary, this study provides additional observational 
evidence that aspirin use is associated with a reduction in 
risk of colorectal cancer for MMR gene mutations carriers. Our 
results suggest that regular long-term use of aspirin or ibu-
profen might be an effective way to reduce colorectal cancer 
risk for this group of highly susceptible people who currently 
rely only on frequent colonoscopies to reduce their risk.
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